The Alliance of U.S. Startups and Inventors for Jobs (USIJ) has submitted formal comments to USTR Ambassador Jamieson Greer in response to the agency’s inquiry on foreign nations freeriding on U.S.-financed innovation. The letter highlights the disproportionate global reliance on American R&D—particularly in the biopharmaceutical sector—and warns that the Trump Administration’s proposed Most Favored Nation (MFN) pricing policy could mirror the very price control regimes that enable this free-riding. USIJ outlines five key recommendations, including rejecting MFN, reinforcing IP diplomacy, and strengthening the U.S. patent system, to protect American inventors and sustain global innovation leadership.
“If the U.S. government proceeds with importing drug price controls from abroad, it will make it virtually impossible for many companies to justify costly biomedical research… and as the pipeline of innovative cures and treatments dries up, U.S. patients—not foreign free-riders—will pay the highest price.”
USIJ Urges Action to End Foreign Free-Riding on American Innovation
The Alliance of U.S. Startups and Inventors for Jobs (USIJ) has submitted formal comments to USTR Ambassador Jamieson Greer in response to the agency’s inquiry on foreign nations freeriding on U.S.-financed innovation. The letter highlights the disproportionate global reliance on American R&D—particularly in the biopharmaceutical sector—and warns that the Trump Administration’s proposed Most Favored Nation (MFN) pricing policy could mirror the very price control regimes that enable this free-riding. USIJ outlines five key recommendations, including rejecting MFN, reinforcing IP diplomacy, and strengthening the U.S. patent system, to protect American inventors and sustain global innovation leadership.